Objective: To explore the clinical efficacy and safety of toracemide in the treatment of acute heart failure. Methods: 320 patients with acute heart failure treated in our hospital from July 2015 to March 2018 were collected as the study subjects, and divided into the control group (furosemide) and the study group (toracemide) according to the random number table. Heart rate, cerebral natriuretic peptide (BNP), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular ejection fraction (LVEF), clinical efficacy and adverse reactions were compared between the two groups before and after treatment. Results: After treatment, heart rate and BNP levels in the study group were significantly lower than those in the control group ( P < 0.05 ). After treatment, LVEDD and LVESD in the study group were significantly lower than those in the control group, and LVEF in the study group was significantly higher than that in the control group ( P <0.05). The total effective rate of the study group was significantly different from that of the control group( P <0.05). The incidence of adverse reactions between the two groups was statistically significant ( P <0.05). Conclusion: Toracemide is effective in the treatment of acute heart failure, can significantly improve cardiac function, reduce heart rate and brain natriuretic peptide, high safety, worthy of clinical application.
Heilongjiang Medicine journal